Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
SHANGHAI, China and CUPERTINO, Calif., Nov. 28, 2016 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that a scientific presentation will be made at the World Stem Cell Summit to be held in West Palm Beach on December 6th-9th, 2016, regarding its advanced mesenchymal progenitor cell (MPC) therapy.
Title: Regeneration of Cartilage by Human Adipose-derived MPC Treatment for Knee Osteoarthritis
Presentation: Thursday, December 8, 11:00AM - 12:00PM EST
Location: Meeting Room 1 G/H, Palm Beach County Convention Center, West Palm Beach, Florida
Presenter: Dr. Richard Wang, Chief Operating Officer of Cellular Biomedicine Group
Following the conference, an archived presentation will be available on the Company website here: http://www.cellbiomedgroup.com/investor-relations/presentations/.
About Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG’s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
Contacts: Sarah Kelly Director of Corporate Communications, CBMG +1 408-973-7884 [email protected] Vivian Chen Managing Director Investor Relations, Citigate Dewe Rogerson +1 347 481-3711 [email protected]
